Anti-amnesic and neuroprotective activities of ANAVEX2-73, a new aminotetrahydrofuran derivative acting as a mixed muscarinic/sigma-1 ligand, in pharmacological and pathological models of amnesia. July 11, 2009
ANAVEX Appoints Dr. Hervé de Kegrohen as CEO to Lead Company Through Clinical Trials and Future Growth June 16, 2009
Anavex Appoints Leading Alzheimer’s Disease Expert Dr. Mark Smith to Scientific Advisory Board February 10, 2009
Ground-Breaking Anti-Amnesic and Neuroprotective Effects of Alzheimer’s Compound ANAVEX 1-41 Published in Journal of Neuropsychopharmacology December 17, 2008
Anavex Presents Neuroprotective Effects of ANAVEX 1-41 at the International Conference on Alzheimer’s Disease 2008 July 30, 2008
Anavex Life Sciences Corp. Will Present New Findings at the International Conference on Alzheimer’s Disease 2008 (July 26-31, 2008, Chicago, USA) June 24, 2008
